187 related articles for article (PubMed ID: 31721462)
1. Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute.
Kodama K; Sonoda K; Kijima M; Yamaguchi S; Yagi H; Yasunaga M; Ohgami T; Onoyama I; Kaneki E; Okugawa K; Yahata H; Ohishi Y; Oda Y; Kato K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e63-e67. PubMed ID: 31721462
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
[TBL] [Abstract][Full Text] [Related]
3. The role of adjuvant therapy in uterine leiomyosarcoma.
Ducie JA; Leitao MM
Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
[TBL] [Abstract][Full Text] [Related]
4. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
5. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
6. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
7. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic characteristics and prognosis factors of uterine sarcomas in central Tunisia].
Khlifi A; Fathallah K; Zbidi C; Hidar S; Bibi M; Khairi H
Bull Cancer; 2014; 101(7-8):669-80. PubMed ID: 25091649
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
10. Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.
Tokunaga H; Takahashi F; Yamamoto H; Honda T; Watanabe T; Shoji T; Sugiyama T; Yamada H; Tando T; Yoshinaga K; Kagabu S; Otsuki T; Kin S; Yokoyama Y; Wagatsuma S; Sato K; Sato H; Oishi T; Yoshida Y; Hayasaka T; Matsui T; Imai N; Nishigori H; Shimokawa H; Yaegashi N; Watanabe Y
Int J Clin Oncol; 2017 Jun; 22(3):541-547. PubMed ID: 28188392
[TBL] [Abstract][Full Text] [Related]
11. [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
Leung F; Terzibachian JJ; Aouar Z; Govyadovskiy A; Lassabe C
Gynecol Obstet Fertil; 2008 Jun; 36(6):628-35. PubMed ID: 18538624
[TBL] [Abstract][Full Text] [Related]
12. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
13. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
14. Uterine leiomyosarcoma metastasizing to the heart.
Tunio MA; Al-Asiri M; Fareed MM
J Coll Physicians Surg Pak; 2014 Mar; 24 Suppl 1():S20-1. PubMed ID: 24717993
[TBL] [Abstract][Full Text] [Related]
15. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
17. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
18. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
[TBL] [Abstract][Full Text] [Related]
20. Uterine leiomyosarcoma: A review of the literature and update on management options.
Roberts ME; Aynardi JT; Chu CS
Gynecol Oncol; 2018 Dec; 151(3):562-572. PubMed ID: 30244960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
